New Molecular Imaging Agent May Help Visualize Early Stages of Alzheimer's Disease, University of Leipzig Study

Published: Jun 08, 2010

ScienceDaily (June 7, 2010) — A multinational clinical trial revealed at the Society of Nuclear Medicine's 57th Annual Meeting presents a novel imaging agent that could be the next major breakthrough for the early detection of Alzheimer's disease -- a slow but fatal neurodegenerative disease. The new agent is used in conjunction with a molecular imaging technique called positron emission tomography (PET) and works by binding to beta-amyloid, a naturally-occurring protein that builds up in the brain and is thought to be a precursor to Alzheimer's. Scientists aim to hone beta-amyloid imaging and put it to use with new drug treatments that could potentially slow or even halt the disease before irreparable damage and dementia set in.

Back to news